Back to results
US 2026/0076899 A1Published application
Targeted release rifaximin compositions
AssigneeBausch Health Ireland Limited
InventorsJacob Cole, Brian R. Rohrs, Daniel J. Stein, Robert J. Israel, Ezra R. Lowe
Life of this patent
Estimating the term…
Abstract
Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.
Claims20
1-171. (canceled)
A rifaximin bead composition comprising a plurality of beads, each bead comprising:
- a substantially spherical sugar substrate;
- a first coating comprising rifaximin and hydroxypropyl methylcellulose acetate succinate (HPMC-AS), wherein the HPMC-AS is present in an amount of from about 20% to about 60% by weight based on the total weight of rifaximin in the composition, or from about 1% to about 12% by weight based on the total weight of the composition;
- and
- a second coating, wherein the second coating is an enteric coating substantially covering the first coating.
1 more element
Dependencies are inferred from the claim text.